

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M. 5999 - SANOFI-AVENTIS / GENZYME

1. On 29 November 2010, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004, by which Sanofi-Aventis . (“Sanofi-Aventis”), a publicly listed *société anonyme* organized under the laws of France, proposes to acquire all of the issued and outstanding stock of Genzyme Corporation (“Genzyme”), a publicly listed company incorporated in the United States of America.

The primary business activities of the undertakings concerned are:

- *Sanofi-Aventis*: Research, development, manufacture and sale of (a) pharmaceuticals used primarily in consumer health care, diabetes, oncology, and emerging markets; (b) human vaccines of five main types: paediatric combination vaccines; influenza vaccines; adult and adolescent booster vaccines; meningitis vaccines; and vaccines for travel-related and endemic exposure to measles, mumps and rubella; and (c) animal health products.
- *Genzyme*: Research, development, manufacture and sale of biotechnology products used in the treatment of rare genetic diseases, cardiometabolic and renal diseases, biosurgery, and hematologic oncology. The company also is engaged in the supply of transplant products, diagnostic products and services, bulk pharmaceuticals, and immune mediated diseases.